Elliott, PM; Anastasakis, A; Asimaki, A; Basso, C; Bauce, B; Brooke, MA; Calkins, H; ... van Tintelen, JP; + view all Elliott, PM; Anastasakis, A; Asimaki, A; Basso, C; Bauce, B; Brooke, MA; Calkins, H; Corrado, D; Duru, F; Green, KJ; Judge, DP; Kelsell, D; Lambiase, PD; McKenna, WJ; Pilichou, K; Protonotarios, A; Saffitz, JE; Syrris, P; Tandri, H; Te Riele, A; Thiene, G; Tsatsopoulou, A; van Tintelen, JP; - view fewer (2019) Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure , 21 (8) pp. 955-964. 10.1002/ejhf.1534.

Preview

Text Protonotarios_AC EJHF MASTER REVISED post acceptance changes.pdf - Accepted Version Download (832kB) | Preview

Abstract

It is 35 years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic architecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associated with a propensity to ventricular arrhythmia have raised many questions about pathogenesis, disease terminology and clinical management. In this paper, we present the conclusions of an expert round table that aimed to summarise the current state of the art in arrhythmogenic cardiomyopathies and to define future research priorities.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item